← Evidence map

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Kazuo Fujihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study). | OpenQuestion